Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regulus Therapeutics Inc. - Common Stock
(NQ:
RGLS
)
8.160
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regulus Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 17, 2023
Via
Benzinga
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics
January 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
December 09, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 08, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.
Via
Benzinga
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
November 03, 2022
Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people.
Via
Benzinga
Earnings Scheduled For August 11, 2022
August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Via
Benzinga
Earnings Scheduled For November 10, 2022
November 10, 2022
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.
Via
Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
September 12, 2022
Via
Benzinga
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
September 13, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
September 12, 2022
Via
Benzinga
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
September 12, 2022
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
Via
Benzinga
Regulus Shares Surge After Early-Stage RGLS8429 Data In Rare Kidney Disease
September 12, 2022
Biopharmaceutical company Regulus Therapeutics Inc (NASDAQ: RGLS) shares jumped after topline safety and Pharmacokinetic (PK) data from its Phase 1 single-ascending dose (SAD) trial of RGLS8429 in...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 12, 2022
Via
Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
September 07, 2022
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
Via
Benzinga
Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday's Mid-Day Session
September 06, 2022
Gainers HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 23, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 03, 2022
Via
Benzinga
Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform
July 25, 2022
Via
Benzinga
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
July 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 18, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
July 15, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
July 07, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 28, 2022
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
June 21, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...
Via
Benzinga
Regulus Gets FDA Orphan Drug Status For Kidney Disease Candidate
June 21, 2022
Regulus Therapeutics Inc. (NASDAQ: RGLS) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its lead drug RGLS8429 in the treatment of Autosomal Dominant Polycystic...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
June 17, 2022
Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 17, 2022
Good morning! We're entering the final day of trading for the week with a look at the biggest pre-market stock movers for Friday!
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
June 16, 2022
Gainers Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 34.4% to $2.81 during Thursday's after-market session. The market value of their outstanding shares is at $29.0 million.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
May 26, 2022
Good morning! We're starting off another day of trading with an overview of the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
7 Penny Stocks With 10x Potential This Year
May 17, 2022
These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit